|
Non-Small Cell Lung Carcinoma
|
0.550 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant tumor of colon
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
|
15760919 |
2005 |
|
Colon Carcinoma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
|
15760919 |
2005 |
|
Squamous cell carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes.
|
18623126 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR and 14-3-3 sigma, CDK10, and p73), all reportedly influence the sensitivity to chemotherapeutic drugs, suggesting that DNA methylation could serve as a molecular marker for predicting the responsiveness of tumors to chemotherapy.
|
19236379 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB.
|
19448676 |
2009 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
|
19634111 |
2009 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Checkpoint with forkhead and ring finger domains (CHFR) is a protein implicated in cancer sensitivity to microtubule-targeting drugs.
|
19634111 |
2009 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Checkpoint with forkhead and ring finger domains (CHFR) is a protein implicated in cancer sensitivity to microtubule-targeting drugs.
|
19634111 |
2009 |
|
Metastatic non-small cell lung cancer
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
|
23386692 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
|
23873170 |
2014 |
|
Malignant neoplasm of stomach
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR is frequently methylated in human gastric cancer, and CHFR methylation may serve as a docetaxel-sensitive marker.
|
24748501 |
2015 |
|
Stomach Carcinoma
|
0.080 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR is frequently methylated in human gastric cancer, and CHFR methylation may serve as a docetaxel-sensitive marker.
|
24748501 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
|
24928946 |
2014 |
|
Colorectal Carcinoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR promoter CpG island methylation, which is associated with MSI, also occurs frequently in MSS CRCs and is a promising prognostic marker in stage II, MSS, BRAF WT CRCs.
|
24928946 |
2014 |
|
Congenital absence of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CHFR expression, analyzed by RNA-seq, was classified as high vs. low based on the median CHFR expression level and correlated with the presence or absence of lung cancer specific mutations (EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA for adenocarcinomas and FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR for squamous cell carcinomas).
|
25477232 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.550 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer.
|
25828518 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
CHFR promoter methylation levels were analyzed in 358 newly diagnosed AML cases and 30 healthy donors by the use of quantitative methylation-specific polymerase chain reaction.
|
26542416 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR acts as a tumor suppressor gene, which is frequently inactivated caused by its promoter hypermethylation in various solid tumors.
|
29115660 |
2018 |
|
Solid Neoplasm
|
0.020 |
PosttranslationalModification
|
phenotype |
BEFREE |
CHFR acts as a tumor suppressor gene, which is frequently inactivated caused by its promoter hypermethylation in various solid tumors.
|
29115660 |
2018 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CHFR plays a role in controlling chromosomal instability and its inactivation will eventually lead to tumorigenesis.
|
30854101 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR is a tumor suppressor that not only recognizes poly(ADP-ribosylation) (PARylation) signals at the sites of DNA damage but also is downregulated in many types of cancer.
|
31812083 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR is a tumor suppressor that not only recognizes poly(ADP-ribosylation) (PARylation) signals at the sites of DNA damage but also is downregulated in many types of cancer.
|
31812083 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CHFR is a tumor suppressor that not only recognizes poly(ADP-ribosylation) (PARylation) signals at the sites of DNA damage but also is downregulated in many types of cancer.
|
31812083 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.550 |
Biomarker
|
disease |
CTD_human |
A panel of seven human EGFR wild-type NSCLC cell lines was characterized for their sensitivity to sequential treatment with cisplatin and erlotinib, and the results were correlated with CHFR.
|
20705357 |
2011 |